What can be learnt from models of incidence rates?

Breast Cancer Research

Volumn 8, Issue 3, 2006, Pages

  Colditz, Graham A ^a   Rosner, Bernard A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; INCIDENCE; LIFESTYLE; RISK FACTOR; THEORETICAL MODEL;

BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LIFE STYLE; MODELS, THEORETICAL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 34247550801     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1414     Document Type: Review

References (66)

1. Kaldor J, Day N: Mathematical models in cancer epidemiology. In Cancer Epidemiology. Edited by Schottenfeld D, Fraumeni J. New York: Oxford University Press; 1996:127-137.
2. Armitage P, Doll R: The age distribution of cancer and a multistage theory of carcinogenesis. Br J Cancer 1954, 8:1-12.
3. Fisher JC, Hollomon JH: A hypothesis for the origin of cancer foci Cancer 1951, 4:916-918.
4. Nordling CO: A new theory on cancer-inducing mechanism. Br J Cancer 1953, 7:68-72.
5. Moolgavkar S: Cancer models. Epidemiol 1990, 1:419-420.
6. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM: Cancer riAk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005, 97:715-723.
7. Doll R, Peto R: Cigarette smoking andDbronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Comm Health 1978, 32:303-313.
8. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319 525-532.
9. Brown C, Chu K: Use of multistage models to infer stage affected by carcinogenic exposure: Example of lung cancer and cigarette smoking. J Chron Dis 1987, 40(Suppl 2):171s-179s.
10. Hazelton W, Clements M, Moolgavkar S: Multistage carcinogenesis and ling cancer mortality in three cohorts. Cancer Epidemiol Bio Prevention 2005, 14:1171-1181.
11. Little M, Hawkins M, Charles M, Hildreth N: Fitting the Armitage-Doll model to radiation-exposed cohorts and implications for population cancer risks. Radiation Research 1992, 132:207-221.
12. Day N: The Armitage-Doll multistage model of carcinogenesis. Stat Med 1990, 9:677-679.
13. Fisher B, Costantino J, Wickerham D, Redmond C, Kavanah M, Cronin W, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al.: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90:1371-1388.
14. Moolgavkar SH, Day NE, Stevens RG: Two-stage model for carcinogenesis: Epidemiology of breast cancer in females. J Natl Cancer Inst 1980, 65:559-569.
15. Moolgavkar S, KnudAon A Jr: Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 1981, 66:1037-1052.
16. Pathak DR, Whittemore AS: Combined effects of body size, parity, and menstrual events on breast cancer incidence in seven countries. Am J Epidemiol 1992, 135:153-168.
17. Pike MC, Kolonel LN, Henderson BE, Wilkens LR, Hankin JH, Feigelson HS, Wan PC, Stram DO, Nomura AM: Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: Risk factoradjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev 2002, 11:795-800.
18. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG: "Hormonal" risk factors, "breast tissue age" and the age-incidence of breast cancer. Nature 1983, 303:767-770.
19. Rosner B, Colditz GA, Willett WC: Reproductive risk factors in a prospective study of breast cancer: The Nurses' Health Study. Am J Epidemiol 1994, 139:819-835.
20. Rosner B, Colditz GL Nurses' health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 1996, 88:359-364.
21. Nunney L: Lineage selection and the evolution of multistage carcinogenesis. Proc Biol Sci 1999, 266:493-498.
22. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ: Biology of disease: Comparison study of human and rat mammary tumorigenesis. Lab Invest 1990, 62:244-278.
23. Armitage P: Multistage models of carcinogenesis. Environ Health Perspect 1985, 63:195-201.
24. Trichopoulos D, Hsieh C, MacMahon B, Lin T, Lowe C, Mirra A: Age at any birth and breast cancer risk. Int J Cancer 1983, 31: 701-704.
25. Janerich DT, Hoff MB: Evidence for a crossover in breast cancer risk factors. Am J Epidemiol 1982, 116:737-742.
26. Lilienfeld AM: The relationship of cancer of the female breast to artificial menopause and marital status. Cancer 1956, 9: 927-934.
27. Trichopoulos D, MacMahon B, Cole P: Menopause and breast cancer risk J Natl Cancer Inst 1972, 48:605-613.
28. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy. Combined reanalysis of data from 51 epidemiological studies involving 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350:1047-1059.
29. Pike M, Ross R, Spicer D: Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 1998, 147:718-721.
30. Rockhill B, Colditz G, Rosner B: Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol 2000, 151: 404-408.
31. Colditz G, Rosner B: Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses' Health Study. Am J Epidemiol 2000, 152:950-964.
32. Colditz G, Frazier A: Models of breast cancer show that risk is set by events of early life: Prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev 1995, 4:567-571.
33. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784-1792.
34. Colditz G, Rosner B, Chen WY, Holmes M, Hankinson SE: Risk factors for breast cancer: According to estrogen and progesterone receptor status. J Natl Cancer Inst 2004, 96:218-228.
35. Yasui Y, Potter J: The shape of the age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 1999, 10:431-437.
36. Tarone R, Chu K: The greater impact of menopause on ERthan ER+ breast cancer incidence: A possible explanation (United States). Cancer Causes Control 2002, 13:7-14.
37. Hulka BS, Chambless L, Wilkinson W, Deubner D, McCarty KS, McCarty KJ: Hormonal and personal effects of estrogen receptors in breast cancer Am J Epidemiol 1984, 119:692-704.
38. Hildreth NG, Kelsey, Eisenfeld AJ, LiVolsi VA, Holford TR, Fischer DB: Differences in breast cancer risk factors according to the estrogen receptor level of the tumor. J Natl Cancer Inst 1983, 70 1027-1031.
39. Nomura A, Tashiro H, Hamada Y, Shigematsu T: Relationship between estrogen receptors and risk factors of breast cancer in Japanese pre- and postmenopausal patients. Breast Cancer Res Treat 1994, 4 37-43.
40. Hislop TG, Coldman AJ, Elwood JM, Skippen DH, Kan L: Relationship between risk factors for breast cancer and hormonal status. Int J Epidemiol 1986, 15:469-476.
41. McTiernan A, Thomas DB, Johnson LK, Roseman D: Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancers. J Natl Cancer Inst 1986, 77:849-854.
42. Stanford JL, Szklo M, Boring CC, Brinton LA, Diamond EA, Greenberg RS, Hoover RN: A case-control study of breast cancer stratified by estrogen receptor status. Am J Epidemiol 1987, 125 184-194.
43. Cooper JA, Rohan TE, Cant EL, Horsfall DJ, Tilley WD: Risk factors for breast cancer by oestrogen receptor status: A population-based case-control study. Br J Cancer 1989, 59:119-125.
44. Kreiger N, King WD, Rosenberg L, Clarke EA, Palmer JR, Shapiro S: Steroid receptor status and the epidemiology of breast cancer. Ann Epidemiol 1991, 1:513-523.
45. Habel LA, Stanford JL: Hormone receptors and breast cancer. Epidemiol Rev 1993, 15:209-219.
46. Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, Folsom AR: Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: How many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 1995, 4:319-326.
47. Yoo KY, Tajima K, Miura S, Takeuchi T, Hirose K, Risch H, Dubrow R: Breast cancer risk factors according to combined estrogen and progesterone receptor status: A case-control analysis. Am J Epidemiol 1997, 146:307-314.
48. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000, 151:703-714.
49. Rich SS, Sellers TA: Genetic epidemiologic methods. In The Genetic Basis of Common Diseases. Edited by King RA, Motulsky AG. New York, NY: Oxford University Press, Inc.; 2002:39-49.
50. Jacobsen O: Heredity in Breast Cancer. London: HK Lewis; 1946.
51. Anderson VE, Goodman HO, Reed SC: Variables Related to Human Breast Cancer. Minneapolis: University of Minnesota Press; 1958.
52. Claus EB, Risch NJ, Thompson WD: Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990, 131: 961-972.
53. Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991, 48:232-242.
54. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250:1684-1689.
55. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 1994, 266:66-71.
56. Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998, 62:145-58.
57. Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004, 23:1111-1130.
58. Wald N, Hackshaw A, Frost C: When can a risk factor be used as a worthwhile screening test? BMJ 1999, 319:1562-1565.
59. Ottman R, Pike MC, King MC, Henderson BE: Practical guide for estimating risk for familial breast cancer. Lancet 1983, 2 556-558.
60. Claus EB, Risch N, Thompson WD: The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993, 28:115-120.
61. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, et al.: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002, 20:2701-2712.
62. Rockhill B, Byrne C, Rosner B, Louie MM, Colditz G: Breast cancer risk prediction with a log-incidence model: Evaluation of accuracy. J Clin Epidemiol 2003, 56:856-861.
63. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999, 91 1829-1846.
64. Tice JA, Cummings SR, Ziv E, Kerlikowske K: Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005, 94 115-122.
65. Baer HJ, Schnitt SJ, Connolly JL, Byrne C, Willett WC, Rosner B, Colditz GA: Early life factors and incidence of proliferative benign breast disease. Cancer Epidemiol Biomarkers Prev 2005, 14 2889-2897.
66. Baer HJ, Schnitt SJ, Connolly JL, Byrne C, Cho E, Willett WC, Colditz GA: Adolescent diet and incidence of proliferative benign breast disease. Cancer Epidemiol Biomarkers Prev 2003, 12 1159-1167.